

**Health Care Fund**  
**SCHEDULE OF INVESTMENTS (Unaudited)**

December 31, 2024

	Shares	Value
<b>COMMON STOCKS<sup>†</sup> - 99.5%</b>		
<b>Pharmaceuticals - 31.9%</b>		
Eli Lilly & Co.	1,167	\$ 900,924
Johnson & Johnson	4,576	661,781
AbbVie, Inc.	3,587	637,410
Merck & Company, Inc.	5,608	557,884
Pfizer, Inc.	16,803	445,784
Bristol-Myers Squibb Co.	6,758	382,232
McKesson Corp.	523	298,063
Becton Dickinson & Co.	1,254	284,495
Zoetis, Inc.	1,709	278,447
AstraZeneca plc ADR	4,101	268,697
CVS Health Corp.	5,658	253,988
Cencora, Inc. — Class A	973	218,614
Teva Pharmaceutical Industries Ltd. ADR*	9,349	206,052
Dexcom, Inc.*	2,483	193,103
Cardinal Health, Inc.	1,600	189,232
Novo Nordisk A/S ADR	2,024	174,104
GSK plc ADR	5,019	169,743
Jazz Pharmaceuticals plc*	1,342	165,267
Novartis AG ADR	1,588	154,528
Alkermes plc*	5,256	151,163
Neurocrine Biosciences, Inc.*	1,001	136,636
Viatis, Inc.	10,613	132,132
Vaxcyte, Inc.*	1,306	106,909
Henry Schein, Inc.*	1,425	98,610
Corcept Therapeutics, Inc.*	1,389	69,992
Option Care Health, Inc.*	3,010	69,832
Madrigal Pharmaceuticals, Inc.*	175	54,000
<b>Total Pharmaceuticals</b>		<b>7,259,622</b>
<b>Healthcare-Products - 29.2%</b>		
Thermo Fisher Scientific, Inc.	961	499,941
Abbott Laboratories	4,380	495,422
Intuitive Surgical, Inc.*	904	471,852
Danaher Corp.	1,882	432,013
Boston Scientific Corp.*	4,534	404,977
Stryker Corp.	1,082	389,574
Medtronic plc	2,989	238,761
Edwards Lifesciences Corp.*	3,156	233,639
Agilent Technologies, Inc.	1,609	216,153
GE HealthCare Technologies, Inc.	2,634	205,926
IDEXX Laboratories, Inc.*	488	201,759
ResMed, Inc.	864	197,588
West Pharmaceutical Services, Inc.	518	169,676
Waters Corp.*	443	164,344
Zimmer Biomet Holdings, Inc.	1,536	162,248
STERIS plc	760	156,226
Natera, Inc.*	975	154,343
Cooper Companies, Inc.*	1,621	149,019
Insulet Corp.*	563	146,982
Hologic, Inc.*	1,936	139,566
Baxter International, Inc.	4,555	132,824
Avantor, Inc.*	6,096	128,443
Align Technology, Inc.*	615	128,234
Bio-Techne Corp.	1,607	115,752
Exact Sciences Corp.*	1,872	105,188
Masimo Corp.*	594	98,188
Repligen Corp.*	656	94,425
Bruker Corp.	1,510	88,516
Lantheus Holdings, Inc.*	963	86,150
Merit Medical Systems, Inc.*	831	80,374
PROCEPT BioRobotics Corp.*	838	67,476
Dentsply Sirona, Inc.	3,528	66,961
Inari Medical, Inc.*	1,206	61,566
Twist Bioscience Corp.*	1,235	57,390
Tandem Diabetes Care, Inc.*	1,555	56,011
TransMedics Group, Inc.*	798	49,755
<b>Total Healthcare-Products</b>		<b>6,647,262</b>
<b>Biotechnology - 21.1%</b>		
Amgen, Inc.	1,579	411,551
Gilead Sciences, Inc.	4,122	380,749
Vertex Pharmaceuticals, Inc.*	845	340,282
Regeneron Pharmaceuticals, Inc.*	431	307,014
Alnylam Pharmaceuticals, Inc.*	812	191,072
Argenx SE ADR*	279	171,585
Biogen, Inc.*	1,093	167,142
Illumina, Inc.*	1,169	156,213
BioNTech SE ADR*	1,271	144,830
United Therapeutics Corp.*	393	138,666
Moderna, Inc.*	3,182	132,308
CRISPR Therapeutics AG* <sup>1</sup>	3,296	129,731
Royalty Pharma plc — Class A	5,045	128,698
BioMarin Pharmaceutical, Inc.*	1,900	124,887
Insmed, Inc.*	1,756	121,234
Sarepta Therapeutics, Inc.*	968	117,699
Incyte Corp.*	1,683	116,245
Exelixis, Inc.*	3,144	104,695
Intra-Cellular Therapies, Inc.*	1,231	102,813
REVOLUTION Medicines, Inc.*	2,175	95,135
Halozyne Therapeutics, Inc.*	1,808	86,441
Legend Biotech Corp. ADR*	2,549	82,944
Roivant Sciences Ltd.*	6,924	81,911
Cytokinetics, Inc.*	1,732	81,473
Blueprint Medicines Corp.*	928	80,940
Ionis Pharmaceuticals, Inc.*	2,284	79,849
Bridgebio Pharma, Inc.*	2,658	72,936
TG Therapeutics, Inc.*	2,393	72,029
Crinetics Pharmaceuticals, Inc.*	1,406	71,889
ADMA Biologics, Inc.*	3,935	67,485

Viking Therapeutics, Inc.*	1,664	66,959
Apellis Pharmaceuticals, Inc.*	2,064	65,862
Axsome Therapeutics, Inc.*	736	62,273
Guardant Health, Inc.*	2,035	62,169
Avidity Biosciences, Inc.*	2,073	60,283
Iovance Biotherapeutics, Inc.*	6,671	49,365
Krystal Biotech, Inc.*	284	44,491
Novavax, Inc.*	4,508	36,244
<b>Total Biotechnology</b>		<b>4,808,092</b>
<b>Healthcare-Services - 16.2%</b>		
UnitedHealth Group, Inc.	1,493	755,249
Elevance Health, Inc.	876	323,156
Cigna Group	1,112	307,068
HCA Healthcare, Inc.	857	257,228
ICON plc*	1,039	217,889
IQVIA Holdings, Inc.*	1,060	208,301
Centene Corp.*	3,265	197,794
Humana, Inc.	738	187,238
Labcorp Holdings, Inc.	672	154,103
Quest Diagnostics, Inc.	944	142,412

**Health Care Fund**  
**SCHEDULE OF INVESTMENTS (Unaudited)**

December 31, 2024

	Shares	Value
<b>COMMON STOCKS<sup>†</sup> - 99.5% (continued)</b>		
<b>Healthcare-Services - 16.2% (continued)</b>		
Molina Healthcare, Inc.*	485	\$ 141,159
Tenet Healthcare Corp.*	930	117,394
Universal Health Services, Inc. — Class B	648	116,264
Charles River Laboratories International, Inc.*	582	107,437
HealthEquity, Inc.*	1,058	101,515
Ensign Group, Inc.	712	94,596
Medpace Holdings, Inc.*	277	92,028
DaVita, Inc.*	589	88,085
Acadia Healthcare Company, Inc.*	1,635	64,828
<b>Total Healthcare-Services</b>		<b>3,673,744</b>
<b>Software - 0.8%</b>		
Veeva Systems, Inc. — Class A*	890	187,122
<b>Internet - 0.3%</b>		
Hims & Hers Health, Inc.*	2,677	64,730
<b>Total Common Stocks</b> (Cost \$15,152,500)		<b>22,640,572</b>
<b>RIGHTS<sup>†††</sup> - 0.0%</b>		
<b>Pharmaceuticals - 0.0%</b>		
Johnson & Johnson Expires 12/31/29	752	—
<b>Total Rights</b> (Cost \$—)		<b>—</b>
		<b>Face Amount</b>
<b>REPURCHASE AGREEMENTS<sup>††,2</sup> - 0.6%</b>		
J.P. Morgan Securities LLC issued 12/31/24 at 4.45% due 01/02/25	\$ 80,726	80,726
BofA Securities, Inc. issued 12/31/24 at 4.43% due 01/02/25	63,454	63,454
<b>Total Repurchase Agreements</b> (Cost \$144,180)		<b>144,180</b>
		<b>Shares</b>
<b>SECURITIES LENDING COLLATERAL<sup>†,3</sup> - 0.1%</b>		
<b>Money Market Fund<sup>****</sup></b>		
First American Government Obligations Fund - Class X, 4.41% <sup>4</sup>	16,116	16,116
<b>Total Securities Lending Collateral</b> (Cost \$16,116)		<b>16,116</b>
<b>Total Investments - 100.2%</b> (Cost \$15,312,796)		<b>\$ 22,800,868</b>
<b>Other Assets &amp; Liabilities, net - (0.2)%</b>		<b>(48,404)</b>
<b>Total Net Assets - 100.0%</b>		<b>\$ 22,752,464</b>

\* Non-income producing security.

\*\*\* A copy of each underlying unaffiliated fund's financial statements is available at the SEC's website at [www.sec.gov](http://www.sec.gov).

† Value determined based on Level 1 inputs.

†† Value determined based on Level 2 inputs.

††† Value determined based on Level 3 inputs.

<sup>1</sup> All or a portion of this security is on loan at December 31, 2024.

<sup>2</sup> Repurchase Agreements.

<sup>3</sup> Securities lending collateral.

<sup>4</sup> Rate indicated is the 7-day yield as of December 31, 2024.

ADR — American Depositary Receipt

plc — Public Limited Company